Intraoperative rescue analgesia
DrugIf signs of inadequate analgesia occur (e.g., >20% increase in heart rate or blood pressure), IV remifentanil infusion rate will be titrated upward within the safety margin.
NCT Number: NCT07105839
This study is designed as a prospective, randomized, controlled clinical trial. It will be conducted in the operating rooms of the University of Health Sciences, Diyarbakır Gazi Yaşargil Training and Research Hospital. Patients aged 18 to 65 years who are scheduled for elective bariatric surgery and meet the inclusion criteria (ASA physical status I-III) will be enrolled in the study.
Eligible patients will be informed both verbally and in writing during their preoperative anesthetic evaluation, and written informed consent will be obtained at least 24 hours prior to surgery.
Patients will be randomly assigned to one of two groups using computer-generated randomization:
Group O (Opioid group)
Group NO (Opioid-free group)
All patients will receive 40 mg IV pantoprazole and 4 mg IV ondansetron 30 minutes before surgery as preoperative medication. Standard ASA monitoring will be applied, and fasting guidelines will be followed. Depth of anesthesia will be monitored in all patients using BIS, and maintained within a target range of BIS 40-60 to ensure adequate depth with no response to surgical stimuli.
Trial opening soon.
Get Notified18 year–65 year
All sexes
Interventional
Phase 4
This study is designed as a prospective, randomized, controlled clinical trial. It will be conducted in the operating rooms of the University of Health Sciences, Diyarbakır Gazi Yaşargil Training and Research Hospital. Patients aged 18 to 65 years who are scheduled for elective bariatric surgery and meet the inclusion criteria (ASA physical status I-III) will be enrolled in the study.
Eligible patients will be informed both verbally and in writing during their preoperative anesthetic evaluation, and written informed consent will be obtained at least 24 hours prior to surgery.
Patients will be randomly assigned to one of two groups using computer-generated randomization:
Group O (Opioid group)
Group NO (Opioid-free group)
All patients will receive 40 mg IV pantoprazole and 4 mg IV ondansetron 30 minutes before surgery as preoperative medication. Standard ASA monitoring will be applied, and fasting guidelines will be followed. Depth of anesthesia will be monitored in all patients using BIS, and maintained within a target range of BIS 40-60 to ensure adequate depth with no response to surgical stimuli.
Anesthesia Protocol:
Group O (Opioid Group):
General anesthesia will be induced with 2 mg/kg propofol, 2 µg/kg fentanyl, and 0.6 mg/kg rocuronium based on ideal body weight (IBW). Maintenance will be achieved using remifentanil (Ultiva®) infusion at 0.1-0.3 µg/kg/min and 1 MAC sevoflurane. Following induction, all patients will receive a bilateral transversus abdominis plane (TAP) block under ultrasound guidance using 40 mL of 0.25% bupivacaine.
Group NO (Opioid-Free Group):
General anesthesia will be induced with 2 mg/kg propofol, 0.5 mg/kg ketamine, and 0.6 mg/kg rocuronium (IBW). Anesthesia will be maintained with dexmedetomidine infusion at 0.2-1.4 µg/kg/h and 1 MAC sevoflurane. Following induction, a bilateral TAP block will also be performed using 40 mL of 0.25% bupivacaine under ultrasound guidance.
Postoperative Analgesia Protocol:
During skin closure, all patients will receive 1 g IV paracetamol and 50 mg IV ketoprofen. At the end of surgery, neuromuscular blockade will be reversed using sugammadex, and patients will be safely extubated.
In the postoperative period, patients will be followed in the surgical ward for 48 hours with a standardized analgesic protocol:
1 g IV paracetamol every 6 hours
4 mg IV ondansetron every 8 hours
50 mg IV ketoprofen every 12 hours
Pain will be assessed using the Visual Analog Scale (VAS). If VAS ≥ 4, 100 mg IV tramadol will be administered as rescue analgesia, and all interventions will be documented in the patient records.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Age 18-65 years
BMI >35
ASA class III-IV
Elective bariatric surgery (e.g., sleeve gastrectomy)
Written informed consent
Exclusion criteria
Refusal to participate
Severe cardiac/pulmonary/psychiatric illness
Allergy to study drugs
Conversion to emergency surgery
Withdrawal at any point by patient or investigator
-
If signs of inadequate analgesia occur (e.g., >20% increase in heart rate or blood pressure), IV remifentanil infusion rate will be titrated upward within the safety margin.
If signs of inadequate analgesia occur (e.g., >20% increase in heart rate or blood pressure), IV dexmedetomidine infusion rate will be titrated upward (up to maximum safe dose).
Time frame: post-op 1.hour (H), 2.H, 3.H, 6.H, 12.H, 18.H, 24.H, 36.H and 48.H
Time frame: 24 Hours and 48 Hours
Time frame: Within 48 hours post-op
IV tramadol
Time frame: 48 hours
Contact information is provided by the study sponsor or research team.
Siirt Training and Research Hospital
Other Gov
A Prospective, Randomized Controlled Trial Comparing Opioid-Free and Opioid-Based Anesthesia in Morbidly Obese Patients Undergoing Bariatric Surgery
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06738043
Agnosia, Bariatric Surgery
View Trial DetailsNCT07636239
Bariatric Surgery, Behavior
Bursa, Turkey (Türkiye)
View Trial DetailsNCT07111767
Avitaminosis, Bariatric Surgery
Peshawar, Khyber Pakhtun Khwa, Pakistan
View Trial DetailsNCT07001215
Apnea, Bariatric Surgery
Madrid, Spain
View Trial Details